Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
REVOLUTION Medicines Inc Market Cap
Based on ratings from 15 stock analysts, the REVOLUTION Medicines Inc stock price is expected to increase by 23.47% in 12 months. This is calculated by using the average 12-month stock price forecast for REVOLUTION Medicines Inc. The lowest target is $63 and the highest is $86. Please note analyst price targets are not guaranteed and could be missed completely.
REVOLUTION Medicines Inc has a total of 15 Wall St Analyst ratings. There are 15 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that REVOLUTION Medicines Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of RVMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Eric Joseph JP Morgan | Overweight | $63 | Maintains | Nov 7, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $70 | Maintains | Nov 7, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $64 | Maintains | Nov 7, 2024 |
| Ami Fadia Needham | Buy | $68 | Maintains | Nov 7, 2024 |
| Michael Schmitz Guggenheim | Buy | $82 | Maintains | Oct 28, 2024 |
| Jay Olson Oppenheimer | Outperform | $60 | Maintains | Oct 28, 2024 |
| Ami Fadia Needham | Buy | $61 | Reiterates | Oct 28, 2024 |
| Ami Fadia Needham | Buy | $61 | Reiterates | Oct 25, 2024 |
| Ami Fadia Needham | Buy | $61 | Reiterates | Oct 24, 2024 |
| Ami Fadia Needham | Buy | $61 | Reiterates | Oct 7, 2024 |
| Peter Lawson Barclays | Overweight | $60 | Maintains | Sep 27, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $56 | Reiterates | Aug 12, 2024 |
| Robert Driscoll Wedbush | Outperform | $59 | Reiterates | Aug 8, 2024 |
| Ami Fadia Needham | Buy | $61 | Maintains | Aug 8, 2024 |
| Eric Joseph JP Morgan | Overweight | $54 | Maintains | Aug 8, 2024 |
| Peter Lawson Barclays | Overweight | $54 | Maintains | Jul 18, 2024 |
| Alec Stranahan B of A Securities | Buy | $55 | Maintains | Jul 16, 2024 |
| Ami Fadia Needham | Buy | $62 | Maintains | Jul 16, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $56 | Maintains | Jul 16, 2024 |
| Jay Olson Oppenheimer | Outperform | $55 | Maintains | Jul 16, 2024 |
When did it IPO
2020
Staff Count
490
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Mark A. Goldsmith Ph.D.
Market Cap
$9.85B
In 2023, RVMD generated $11.6M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RVMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Revolution Medicines (Nasdaq: RVMD) will host an investor webcast to update on its RAS(ON) inhibitor portfolio for RAS-addicted cancers on Nov. 27, 2024.
Why It Matters - Revolution Medicines' webcast on RAS(ON) inhibitors signals potential advancements in cancer therapies, which could impact stock performance and attract investor interest.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Revolution Medicines, Inc. (RVMD) held its Q3 2024 earnings call, discussing financial results and updates on their drug development pipeline. Detailed figures and forecasts were provided.
Why It Matters - Revolution Medicines' Q3 2024 earnings reveal financial health, growth prospects, and operational performance, influencing stock valuation and investor sentiment.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A Phase 3 trial for RMC-6236 is in progress, targeting patients with metastatic pancreatic ductal adenocarcinoma, backed by a strong clinical profile.
Why It Matters - The initiation of a Phase 3 trial for RMC-6236 in metastatic PDAC may signal potential breakthroughs in treatment, impacting future revenue and stock performance for involved biotech companies.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Revolution Medicines CEO Mark A. Goldsmith will speak at Guggenheim's Healthcare Innovation Conference and UBS Global Healthcare Conference, highlighting the company's focus on targeted cancer therapies.
Why It Matters - Mark A. Goldsmith's participation at major healthcare conferences highlights Revolution Medicines' visibility and credibility, potentially attracting investors and partnerships in the oncology sector.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Revolution Medicines (Nasdaq: RVMD) will report Q3 2024 financial results on November 6, 2024, after market close, followed by a management webcast at 4:30 p.m. ET.
Why It Matters - Revolution Medicines' upcoming financial results and corporate update may impact stock performance, investor sentiment, and market perceptions of its pipeline in RAS-addicted cancer therapies.
Fri, 25 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - RMC-9805, a RAS(ON) G12D-selective inhibitor, shows promising tolerability and antitumor effects in patients with pancreatic ductal adenocarcinoma (PDAC) based on initial clinical results.
Why It Matters - Positive clinical results for RMC-9805 suggest potential market growth for the company, enhancing its valuation and attracting investor interest in oncology sectors.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
